Arnica / Urtica urens ointment
Available from pharmacies, supermarkets, and retail outlets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 28 studies.
Reviews & meta-analyses: 2 · Randomised trials: 2 · 1998–2025
Showing all 28 studies, sorted by most relevant.
Claudia-Crina Toma, M. Marrelli, Monica Puticiu, et al.
Plants, 2024
Arnica L. genus (Asteraceae) comprises perennial herbs native to the temperate and boreal parts of the northern hemisphere. Arnica montana is the main species. It shows different biological activities, such as antioxidant, anti-inflammatory, antibacterial, antifungal, and antitumor effects. The Arnica formulations are mainly used for pain management. This systematic review is aimed at summarizing the studies focusing on the use of Arnica products on pain and inflammatory signs due to traumatic injuries related to sport and surgical interventions as well as to arthritis and other inflammatory conditions. Both phytotherapeutic and homeopathic formulations are taken into account. This paper only includes manuscripts published in mainstream journals. A literature search from Scopus, Web of Science, and PubMed databases has been carried out using a combination of the keywords “Arnica”, “trauma”, “sport”, “injury”, “injuries”, and “pain”. According to the search strategy and inclusion criteria for this study, 42 eligible papers, focusing on both Arnica alone and formulations containing a mixture of plant extracts, have been finally selected. This review critically discusses the in vitro, in vivo, and clinical studies dealing with Arnica products, reporting both positive and negative outcomes, thus providing perspectives for future research on the plant pharmacological potential.
Abstract licence: CC BY
A. Robertson, R. Suryanarayanan, A. Banerjee
Homeopathy, 2007
- Arnica
- Homeopathy
- Phytotherapy
Chintamani Nayak, Nivedita Pattanaik, A. Chattopadhyay, et al.
Journal of Complementary and Integrative Medicine, 2020
- Materia Medica
- Hyperuricemia
- Mothers
E. Erkan, Kudret Parpar, T. Develi, et al.
The European Research Journal, 2018
Objectives: The aim of this placebo-controlled study was to assess the efficacy of single dose homeopathic Arnica montana 200 CH in dental surgeries.Methods: The study included 79 patients undergoing wisdom teeth extractions, implant placements, cystectomies, augmentation procedures, alveoloplasties, lefort-1 osteotomies at Istanbul Medipol University’s Department of Oral and Maxillofacial Surgery. The patients were randomly divided into two groups using a computer program. Three globulesof Arnica montana 200 CH were administered in the sublingual area in the patients group 1, and glucose globules were administered in the sublingual area in the patients into group 2. After each patient’s surgical operation, the surgeoncompleted a survey about operation time and scope. In addition,a self-assessment survey was completed by the patients the day after their operationsto evaluate their post-operational swelling and pain.Results: Arnica montana did not appear to significantly prevent post-operative swelling and pain when compared to the placebo (p < 0.05). Conclusions: This study showed that the use of Arnica montana before a physically traumatic procedure is not more effective than the use of a placebo. However, the results should be evaluated in other studies, including the administration of Arnica montana after a physically traumatic procedure to clearly demonstrate its homeopathic efficiency.
Abstract licence: CC BY-NC-ND
B. M. Seeley, A. Denton, M. Ahn, et al.
Archives of Facial Plastic Surgery, 2006
- Rhytidoplasty
- Arnica
- Contusions
E. Ernst, M. H. Pittler
Archives of Surgery, 1998
- Phytotherapy
- Plants, Medicinal
- Clinical Trials as Topic
J. Verre, M. Boisson, A. Paumier, et al.
Journal of ethnopharmacology, 2023
- Biological Products
- Arnica
- Inflammation
U. Khanvilkar, H. Patil, S. Bandekar, et al.
Clinics and Practice, 2023
The pushout bond strength of root fillings at radicular dentin was investigated employing NaOCl, CHX, and homoeopathic mother tincture (Arnica montana) as an irrigant. Sixty human permanent single-rooted extracted teeth were decoronated. The root canals were instrumented using Pro taper universal rotary system (Dentsply Tulsa Dental; Tulsa, Oklahoma) and were prepared up to F3 apical size. The roots were then randomly divided into three groups according to irrigation solution (n = 20) according to the final irrigation regimen: Group I: 3 mL 5.25% NaOCl followed by 3 mL Saline (control); Group II: 3 mL Arnica montana (10%, w/v) followed by 3 mL Saline; Group III: 3 mL CHX followed by 3 mL Saline. The canals were dried using paper points. The canals were coated with AH Plus sealer (Dentsply DeTey, Konstaz, Germany) with the aid of a Lentulo spiral (Dentsply DeTey, Konstaz, Germany) and obturated with #F3 gutta-percha. Each root was then horizontally sliced into three slices, labelled coronal, middle, and apical, each measuring 2 mm thick. Furthermore, at a crosshead speed of 2 mm/min, the test was carried out using the universal testing apparatus. The 5.25% NaOCl significantly decreased the bond strength of AH Plus to dentin. Both CHX and Arnica montana were capable of reversing the compromised pushout of AH Plus to NaOCl-treated dentin. After using NaOCl as an irrigant, the danger of diminished binding capacity of AH Plus to root canal walls arises. Final irrigation with Arnica montana and CHX reduces this risk.
Abstract licence: CC BY
A. Kawakami, C. Sato, T. N. Cardoso, et al.
Evidence-based Complementary and Alternative Medicine : eCAM, 2011
The effects of Arnica montana 6cH on the individual modulation of acute inflammation kinetics in rats were evaluated. Adult male Wistar rats were inoculated with 1% carrageenan into the footpad and treated with Arnica montana 6cH, dexamethasone (4.0 mg/kg; positive control) or 5% hydroalcoholic solution (negative control), per os, each 15 minutes, between 30 and 180 minutes after the irritant inoculation. Histopathological and immunohistochemistry procedures were done in order to get a panel of inflammatory positive cells for CD3 (T lymphocytes), CD45RA (B lymphocytes), CD18 (beta 2 integrin), CD163 (ED2 protein), CD54 (ICAM-1), and MAC 387 (monocytes and macrophages). The statistical treatment of data included a posteriori classification of animals from each group (N = 20) in two subgroups presenting spontaneous precocious or late oedema. Animals that presented precocious oedema were less responsible to Arnica montana 6cH in relation to hemodynamic changes. Instead, rats that exhibited late oedema presented less intense oedema (P = .01), lower percentage of mast cell degranulation (P = .0001), and increase in lymphatic vessels diameter (P = .05). The data suggest an individually qualitative adjustment of inflammatory vascular events by Arnica montana 6cH.
Abstract licence: CC BY
S. Dokania, H. Shekhar, P. Aphale
International Journal of High Dilution Research - ISSN 1982-6206, 2025
Introduction: Bone tissue engineering is a promising field in regenerative medicine. Human umbilical mesenchymal stem cells (hUMSCs) and osteoblasts are key players in bone regeneration. hUMSCs, derived from umbilical cords, possess the potential to differentiate into bone-forming cells. Materials and Methods: This study investigated the cytotoxicity (MTT Assay) of homeopathic preparations of Ledum palustre, Arnica montana, and Ruta graveolens at a concentration of 0.10 µg/mL (48 hours post MTT Assay). The osteogenic differentiation potential of hUMSCs was evaluated by quantifying the percentage of cells transformed into osteoblasts. Following established protocols, hUMSCs were isolated, cultured, and characterized using flow cytometry. Results: Treatment with Ruta graveolens 30C was found to enhance the osteogenic differentiation of hUMSCs. The findings of this study contribute to understanding the effects of homeopathic medicines on stem cell behavior and may pave the way for their clinical application in bone regeneration.
Abstract licence: CC BY-NC-SA
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.